Envisioning the Challenges of Pharmaceutical Industry 5.0: An Argumentative Analysis

Abstract

The Pharmaceutical Industry 5.0 is an essential stage in the progression of the pharmaceutical sector, carrying the achievements of Industry 4.0. This evolution seeks to introduce changes within the sector with the help of such determinants as an individual approach, quality, sustainability, and human-centricity. Industry 5.0 focuses on medicine by applying new and enhanced methods, such as artificial intelligence (AI) or machine learning (ML) in conjunction with human cognition, to customize every patient’s treatment. This is important for using AI and ML as data accuracy, security, and interoperability are success factors. Compliance with regulations is challenging due to the strict and continuously changing nature of regulations in this industry, while trying to grasp new technologies. There is a trend of relationships between pharmaceutical companies, technology suppliers, academia, and regulatory organizations in sharing knowledge materials and capabilities, as well as risks and responsibilities, to speed up new approaches and methods and to meet regulatory needs. This helps speed up the drug discovery process, drug development, and manufacturing due to the efficiency of data analysis. Telemedicine, wearable devices, and mobile health apps expand as digital health technologies enter the pharmaceutical market, allowing the gain of real-time health information. The industry is shifting toward the targeted and specific development of medicines based on large amounts of data. These tools allow the creation of treatment pathways particular to the patient’s disease, thereby improving the efficacy and safety of the medical actions. The integration of technology in the manufacturing process enhances manufacturing.

Ähnliche Arbeiten